Alketa Hamzaj

3.4k total citations · 1 hit paper
13 papers, 295 citations indexed

About

Alketa Hamzaj is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Alketa Hamzaj has authored 13 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Surgery. Recurrent topics in Alketa Hamzaj's work include Renal cell carcinoma treatment (4 papers), Prostate Cancer Treatment and Research (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Alketa Hamzaj is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Prostate Cancer Treatment and Research (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Alketa Hamzaj collaborates with scholars based in Italy, United States and United Kingdom. Alketa Hamzaj's co-authors include María T. Bourlon, Cristina Suárez, Bernard Escudier, Burçin Şimşek, Amishi Y. Shah, Yoshihiko Tomita, Toni K. Choueiri, Robert J. Motzer, Thomas Powles and Elizabeth R. Kessler and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Journal of Thoracic Oncology.

In The Last Decade

Alketa Hamzaj

13 papers receiving 290 citations

Hit Papers

Nivolumab plus cabozantinib versus sunitinib in first-lin... 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
    2022 177 citations Robert J. Motzer, Thomas Powles et al. The Lancet Oncology profile →

Peers

Alketa Hamzaj
Annelies Verbiest Belgium
Marco Brugia Italy
Daniela Cullurà Italy
Graciela Cruz‐Rico Mexico
Darren M. Kocs United States
Guilherme Harada Brazil
Luigi Cerbone Italy
Landon C. Brown United States
Annalisa Guida Italy
Letizia Laera Italy
Annelies Verbiest Belgium
Alketa Hamzaj
Citations per year, relative to Alketa Hamzaj Alketa Hamzaj (= 1×) peers Annelies Verbiest

Countries citing papers authored by Alketa Hamzaj

Since Specialization
Citations

This map shows the geographic impact of Alketa Hamzaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alketa Hamzaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alketa Hamzaj more than expected).

Fields of papers citing papers by Alketa Hamzaj

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alketa Hamzaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alketa Hamzaj. The network helps show where Alketa Hamzaj may publish in the future.

Co-authorship network of co-authors of Alketa Hamzaj

This figure shows the co-authorship network connecting the top 25 collaborators of Alketa Hamzaj. A scholar is included among the top collaborators of Alketa Hamzaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alketa Hamzaj. Alketa Hamzaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Motzer, Robert J., Thomas Powles, Mauricio Burotto, et al.. (2022). Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. The Lancet Oncology. 23(7). 888–898. 177 indexed citations breakdown →
3.
4.
Powles, Thomas, Toni K. Choueiri, Mauricio Burotto, et al.. (2022). Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 40(6_suppl). 350–350. 16 indexed citations
5.
Giorgi, Ugo De, Sarah Scagliarini, Umberto Basso, et al.. (2017). Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).. Journal of Clinical Oncology. 35(15_suppl). 4577–4577. 1 indexed citations
6.
Bracarda, Sergio, et al.. (2015). Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies. Seminars in Oncology. 42(3). 495–505. 36 indexed citations
7.
Bracarda, Sergio, Claudia Caserta, Luca Galli, et al.. (2015). Docetaxel Rechallenge in Metastatic Castration-Resistant Prostate Cancer: Any Place in the Modern Treatment Scenario? An Intention to Treat Evaluation. Future Oncology. 11(22). 3083–3090. 8 indexed citations
8.
9.
Gori, Stefania, Jennifer Foglietta, Marta Rossi, et al.. (2014). Sunitinib therapy in metastatic papillary thyroid cancer.. PubMed. 99(6). 285e–7e. 7 indexed citations
10.
Bracarda, Sergio, Giuseppe Procopio, Daniele Alesini, et al.. (2014). Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.. Journal of Clinical Oncology. 32(15_suppl). e16058–e16058. 1 indexed citations
11.
Bracarda, Sergio, et al.. (2013). GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Critical Reviews in Oncology/Hematology. 89(3). 386–393. 16 indexed citations
12.
Gori, Stefania, Jennifer Foglietta, Marta Rossi, et al.. (2013). Sunitinib therapy in metastatic papillary thyroid cancer. Tumori Journal. 99(6). e285–e287. 6 indexed citations
13.
Crinò, Lucio, Jennifer Foglietta, & Alketa Hamzaj. (2007). Lung Cancer. Journal of Thoracic Oncology. 2(5). S24–S26. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annelies Verbiest Breakdown of academic impact, for papers by Marco Brugia Breakdown of academic impact, for papers by Daniela Cullurà Breakdown of academic impact, for papers by Graciela Cruz‐Rico Breakdown of academic impact, for papers by Darren M. Kocs Breakdown of academic impact, for papers by Guilherme Harada Breakdown of academic impact, for papers by Luigi Cerbone Breakdown of academic impact, for papers by Landon C. Brown Breakdown of academic impact, for papers by Annalisa Guida Breakdown of academic impact, for papers by Letizia Laera
Rankless by CCL
2026